Towards Healthcare
Cell and Gene Therapy Manufacturing QC Market to Rise at 16.89% CAGR till 2034

Cell and Gene Therapy Manufacturing QC Market Driving Personalized Care

Based on market forecasts, the global cell and gene therapy manufacturing QC market, projected at USD 2.66 billion in 2024, is expected to reach USD 12.35 billion by 2034, growing at a CAGR of 16.89% over the forecast period. The growing demand for cell and gene therapy and stringent regulatory policies drive the global market. North America dominated the global market due to rapidly expanding manufacturing infrastructure and the presence of key players

Content

  • Insight Code: 6100
  • No. of Pages: 150+
  • Format: PDF/PPT/Excel
  • Published: September 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

About The Author

Rohan Patil is a seasoned market research professional with over 5 years of focused experience in the healthcare sector, bringing deep domain expertise, strategic foresight, and analytical precision to every project he undertakes.

He began his journey with Precedence Research, where he played a pivotal role in developing high-impact healthcare market reports. Today, Rohan leads research initiatives at Towards Healthcare, while also contributing to Statifacts, where he supports cross-industry analysis and data-driven storytelling.

Rohan’s core strengths lie in trend analysis and emerging technologies, regulatory monitoring and thought leadership through high-quality report writing. He excels at identifying future-ready opportunities and translating complex data into strategic recommendations. His work spans pharmaceuticals, biotechnology, medical devices, and digital health, assessing everything from market potential and competitive positioning to customer needs and regulatory shifts.

A trusted advisor and a relentless innovator, Rohan continues to push the boundaries of traditional market research, merging scientific rigor with commercial insight to stay ahead in a fast-evolving healthcare landscape.

Talk to us
FAQ's

The cell and gene therapy manufacturing QC market currently in 2025 records USD 3.11 billion and is anticipated to grow to USD 12.35 billion by 2034, advancing at a CAGR of 16.89% from 2024 to 2034.

North America is leading the cell and gene therapy manufacturing QC market due to the availability of state-of-the-art research and development activities, favorable regulatory policies, and the presence of key players.

Some key players include Thermo Fisher Scientific, Eurofins Scientific, and IQVIA.

Key trends include the growing demand for cell and gene therapy, increasing investments and collaborations, and technological advancements.

The typical critical attributes of CGTs are safety, purity, identity, quantity, potency, and stability.

Food and Drug Administration, BioSpectrum India, India Brand Equity Foundation, National Medical Products Administration, GOV.UK
Any Questions